Transcatheter aortic valve replacement for the American literature or transcatheter aortic valve implantation (TAVI) for the European scientific community, has become the treatment of choice for patients with severe aortic valve stenosis not amenable to surgical treatment for their high risk. Recent evidences further the scope of this procedure extending its indication also for patients at intermediatehigh surgical risk. Albeit the data presently available support favourable clinical outcome for this procedure when compared with traditional surgical intervention (SAVR: surgical aortic valve replacement), the occurrence of cerebrovascular adverse events has been the most dreaded complication of this technique. Several neuroimaging studies with magnetic resonance (MR), detected an high incidence of new ischaemic cerebral perfusion defects after TAVI, regardless of the type of valve or the vascular access utilized. Most of the cerebral perfusion defects reported were clinically silent, nonetheless the occurrence of symptomatic events averaged 3.5%, among the highest reported after cardiovascular interventional procedures. 1 Results from large registries reported, for patients at high surgical risk or inoperable, a stroke risk after TAVI between 1.7% and 4.8%. 2 The more recent Placement of Aortic Transcatheter Valves (PARTNER)-2 study, randomized 2032 patients with severe aortic stenosis but at intermediate surgical risk, to TAVI or SAVR. The results of the trial after 2 years showed a similar incidence of overall mortality and stroke for the two procedures (19.3% TAVI vs. 21.1% SAVR; P ¼ 0.25). The incidence of ischaemic cerebral events was as well similar both in the acute phase and in the follow-up. 3 The pathogenesis of stroke after TAVI is typically embolic rather than atherothrombotic or haemorrhagic. From a pathophysiology stand-point both procedure-dependent and prosthesis-dependent factors, seems to be involved; furthermore, the 'intrinsic' cardioembolic risk of the patient should be considered, standing the high prevalence of pre-existing or new-onset atrial fibrillation (AF) in this condition. An observational study by Nombela-Franco et al. evaluated the temporal incidence of cerebrovascular ischaemic events after TAVI. The higher risk was observed during the first few hours immediately after the procedure. In fact, the study showed that acute events (within the first 24 h after the procedure) were mainly secondary to procedure dependent mechanical factors. On the other hand, subacute events (1-30 days after TAVI) were related to new-onset AF. Late events (30 days to 1 year after TAVI) correlated with pre-existing AF, increased atherosclerotic burden (peripheral and cerebrovascular arterial disease), and other well-known cardiovascular risk factors. 4 The European Guidelines recommends aspirin for 3 months (class IIa), rather than oral anticoagulants (class IIb) 5 ; the American Guidelines by the American Heart Association/ American College of Cardiology (AHA/ACC) recommend long-term aspirin [class IIa; level of evidence (LOE): B], or anticoagulation with vitamin K antagonist with international normalized ratio target of 2.5 for at least 3 months and up to 6 months for patients at low bleeding risk (class IIa; LOE: B) 6 ; furthermore, the American College of Chest Physicians (ACCP) Guidelines support aspirin use (50-100mg/day) over oral anticoagulation for patients in sinus rhythm and no other contraindication to anticoagulation (Grade 2 according to ACCP categories). 7 Presently, the choice of optimal antithrombotic therapy cannot be made without a global evaluation of the haemorrhagic and thromboembolic individual risk. Post-TAVI bleeding complications are frequent and carry negative prognostic implications. The risk of bleeding remains high even beyond the acute phase, as shown by an analysis of 2401 post-TAVI patients in whom the incidence of major bleeding episodes was 5.9% during the first year, mostly gastrointestinal and neurologic. 8 Major bleeding episodes were independent predictor of mortality, during the subacute and successive phase. Accordingly, despite the lower frequency of thrombotic events vis-à-vis the higher risk of bleeding, oral anticoagulant treatment cannot be recommended for all patients after TAVI without further supportive evidence. It is clear that new oral anticoagulants, providing a lower haemorrhagic risk and thus a more advantageous safety profile, could represent the best therapeutic strategy, considering that their safety is not inferior to antiplatelet drugs. 9 The results of the studies underway will clarify which one is the optimal antithrombotic therapy for these patients. In the daily clinical practice, the priority is still an individualized clinical approach evaluating the clinical and procedural characteristics of every single patient.
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